TRANSCODE THERAPEUTICS INC (RNAZ) Stock Analyst Earnings Estimates
NASDAQ:RNAZ - Nasdaq - US89357L3033 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -100.00% | N/A | N/A -100.00% | N/A | N/A 180.81% | N/A 86.69% | |||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -6.109M | -18.535M -203.43% | -19.295M -4.10% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -384K | -456.9K -18.98% | -726.6K -59.03% | -6.151M -746.56% | -18.634M -202.93% | -19.419M -4.21% | N/A 33.29% | N/A 4.72% | N/A -33.06% | N/A -123.60% | N/A 27.22% | N/A 6.11% | N/A 42.28% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -61.45% | N/A 79.22% | N/A 99.94% | N/A 8.19% | N/A 77.57% | N/A -708.16% | N/A 92.17% | N/A 6.45% | N/A 41.38% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.27 85.66% | -1.51 91.53% | -1.67 92.96% | -1.04 80.30% | -0.80 75.70% |
| Revenue Q2Q % growth | 306K | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.142M 47.23% | -2.652M 19.37% | -2.958M 42.16% | -3.162M -46.02% | -3.468M -61.90% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -5.28 92.14% | -16.49 | 11.21 | 67.99% |
| Q2 2024 Q2Q % growth | -23.76 81.95% | -19.52 | -4.24 | -21.70% |
| Q1 2024 Q2Q % growth | -17.82 | -23.56 | 5.74 | 24.37% |
| Q4 2023 Q2Q % growth | -22.84 92.86% | -11.02 | -11.82 | -107.33% |
| Q3 2023 Q2Q % growth | -67.20 74.55% | -61.20 | -6.00 | -9.80% |
| Q2 2023 Q2Q % growth | -131.60 54.31% | -138.31 | 6.71 | 4.85% |
| Q4 2022 Q2Q % growth | -320.00 -73.91% | -310.08 | -9.92 | -3.20% |
| Q3 2022 Q2Q % growth | -264.00 -131,900.00% | -326.40 | 62.40 | 19.12% |
| Q2 2022 Q2Q % growth | -288.00 | -244.80 | -43.20 | -17.65% |
| Q4 2021 Q2Q % growth | -184.00 | -204.00 | 20.00 | 9.80% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 306K | -306K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -970% | -723.08% | 92.16% | -131.07% |
| Revenue | 0% | N/A | 0% | -40% |